3 Biotech Stocks You Can Buy and Hold for the Next Decade
Investing in biotech companies can be hard to figure out. Great science and early-stage success doesn't always translate into drug approvals. In fact, only 10% of drug candidates that enter phase 1 trials will make it to the market. Still, the potential returns from a blockbuster drug lead many to buy shares and hope for the best.
Another approach is to buy a past winner that has the ability to spread its bets on research and development. Although the upside might not be as great, a drugmaker with cash coming in the door has a much greater margin of safety than a small company with all its eggs in one basket.
That's why I like Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Seagen (NASDAQ: SGEN). Here's how each is leveraging past success for future growth.
Source Fool.com
